Editas Gains Australian Approval to Start First-in-Human Trial of EDIT-401 for Hypercholesterolemia

What happened

Editas Medicine announced that it has received approval to initiate a Phase I/II clinical trial of EDIT-401 in Australia, marking a key regulatory step toward first-in-human testing. EDIT-401 is an in vivo CRISPR-based therapy designed to upregulate the LDL receptor gene in the liver to lower LDL cholesterol, and preclinical data in non-human primates showed roughly 90% LDL-C reduction after a single dose. The master report had identified an IND/CTA by mid-2026 as a critical milestone, and this approval indicates Editas is executing on that timeline, albeit in Australia where regulatory requirements may differ from the FDA. However, the company remains pre-revenue with significant cash burn, and the trial is only the beginning of a long clinical path; positive safety and efficacy data will be needed to validate the platform. The stock has been volatile and recently traded around $2.06, with the investment thesis hinging on successful human proof-of-concept by year-end 2026.

Implication

For investors, this approval confirms that Editas is on track to start human dosing, which supports the base case of the master report that an IND/CTA would be accepted by mid-2026. However, the Australian approval does not guarantee that the FDA will accept an IND on a similar timeline, so the US regulatory path remains a key risk. Furthermore, the stock still trades at a low enterprise value relative to cash, but the company's ability to reach proof-of-concept by year-end 2026 is not assured. Positive initial data would likely re-rate the stock toward the $3.50 base case, while setbacks could push it toward the $1.00 bear case. Given the binary nature of the event, position sizing should remain modest until early human data are reported.

Thesis delta

The thesis is modestly strengthened by the approval, as it reduces the probability of a near-term regulatory delay in the EDIT-401 program. However, the core value driver remains the demonstration of clinical efficacy and safety in humans, which is still outstanding. The master report's scenarios remain largely unchanged; the approval pushes the probability distribution slightly toward the base case but does not yet justify moving to a higher conviction level.